Reiterated Aslan Pharmaceuticals Ltd (ASLN) Rating.
EU: On Wednesday morning, analysts report was shared with investors and clients of Aslan Pharmaceuticals Ltd (ASLN). Its “Buy” Rating reiterated by H.C. Wainwright. Equity research analysts have price target of $8.5 which would suggest 142.86 % upside potential on firm’s stock.
ASLN is reaching $3.5 during the last trading session, after decreased 0.57%.Currently ASLAN Pharmaceuticals Limited is after 0.00% change in last February 28, 2018. ASLN has also 12,388 shares volume. ASLN by 0.00% the S&P500.
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers.The company has $115.82 million market cap. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe.Currently it has negative earnings. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
For more ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) news announced recently go to: Globenewswire.com, Seekingalpha.com, Benzinga.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients – GlobeNewswire” announced on October 22, 2018, “ASLAN Pharmaceuticals completes enrollment in TreeTopp study – Seeking Alpha” on January 02, 2019, “84 Biggest Movers From Yesterday – Benzinga” with a publish date: February 28, 2019, “ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director – GlobeNewswire” and the last “ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting – GlobeNewswire” with publication date: November 01, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.